Results from a recent population-based cohort study have indicated that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may increase the risk of developing neovascular age-related macular degeneration (nAMD) in patients with diabetes.1 GLP-1 RAs are one of the most beneficial treatments for type 2 diabetes; it increases glucose transporter expression in pancreatic cells, which facilitate glucose … Read more
Groundbreaking advancements in MASH cirrhosis treatment are rapidly emerging.Discover how GLP-1 and FGF21 analogs are reshaping the landscape of liver disease management,offering renewed hope for those affected. Recent studies highlight the potential of these novel drug therapies to significantly improve outcomes and revolutionize patient care. This article dives deep into the science, exploring the mechanisms … Read more
Streamlining GLP-1 prior Authorizations: A New Era of Efficiency The prior authorization (PA) process for glucagon-like peptide-1 (GLP-1) medications has long been a source of frustration for both health care providers and patients. The administrative burden, potential for errors, and resulting delays in treatment initiation can significantly impact patient outcomes. Tho, advancements in electronic prior … Read more
Semaglutide side effects solved? Scientists target nerve cells responsible for nausea-free weight loss nutritioninsight.com Scientists Flip the Brain’s “Fat-Off” Switch – Weight Loss Without Side Effects SciTechDaily Tiny Brain Cell Cluster Found to Drive Obesity and Overeating Neuroscience News Source link
Four leading organizations in lifestyle medicine, obesity medicine, and nutrition-the American College of Lifestyle Medicine (ACLM), the American Society for Nutrition (ASN), the Obesity Medicine Association (OMA), and The Obesity Society (TOS)-have jointly released a clinical advisory titled “Nutritional Priorities to Support GLP-1 Therapy for Obesity.” Published across four peer-reviewed journals, this consensus-based guidance reflects … Read more
“`html Table of Contents BREAKING: GLP-1 Access Improving, But Hurdles Remain Key Findings Limitations Noted Conclusion BREAKING: GLP-1 Access Improving, But Hurdles Remain By Amelia Smith | WASHINGTON… The post GLP-1 Coverage: Yearly Trends for Weight Loss 2024 appeared first on NewsyList. Source link
The Silent Risk: Why Type 2 Diabetes Impacts Women Differently Table of Contents The Silent Risk: Why Type 2 Diabetes Impacts Women Differently Delayed Diagnosis and Increased Severity in Women The Diagnostic Gap: Why Are Women Being Missed? The Role of Hormonal Fluctuations Pregnancy as a Predictive Factor The Shifting Landscape of Fat Storage Women … Read more
Statistically, men are more likely than women to be diagnosed with type 2 diabetes, with about 18 million more men living with the condition worldwide. This doesn’t tell the whole story. When women do get a diagnosis, they’re often older and have a higher body fat mass. They’re also more likely to die from diabetes-related … Read more
Los Angeles — New research presented today at the American Psychiatric Association’s Annual Meeting shows that GLP-1 receptor agonists may be able to help cigarette smokers reduce weight gain while they are quitting. A team led by Debora Xavier, M.D., conducted a systematic review and meta-analysis to determine how abstinence from cigarettes and post-cessation weight … Read more
GLP-1 analogues have revolutionised the management of obesity and type 2 diabetes; however, health experts say that they come with real risks and limitations that patients should be aware of. In an interview with HT Lifestyle, Dr Jaison Paul Sharma, MBBS, MD (Internal Medicine) – consultant diabetologist at Sharma Hospital in Garhdiwala, revealed that “common … Read more